Medesis Pharma SA - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Medesis Pharma SA are shown below. The SDG rating for Medesis Pharma SA indicates the company's transparency towards the UN SDGs. Full Sustainability assessment of Medesis Pharma SA are accessed by registering for free.
Medesis Pharma SA in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 0.9; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.7.
0.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Analytik Jena AG | 8.0 | High |
| 1 | Amniotics AB (publ) | 8.0 | High |
| ... | ... | ... | |
| 158 | Aralez Pharmaceuticals Canada Inc | 1.2 | Low |
| 158 | Zeltia SA | 1.2 | Low |
| 162 | Medesis Pharma SA | 0.9 | Low |
| 162 | Allmed Solutions Ltd | 0.9 | Low |
| 162 | Healthconn Corp | 0.9 | Low |
| 182 | Wesana Health Holdings Inc | 0.0 | Low |
| 182 | rEVO Biologics Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Medesis Pharma SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Medesis Pharma SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Medesis Pharma SA report the average age of the workforce?
Sign up for free to unlockDoes Medesis Pharma SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Medesis Pharma SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Medesis Pharma SA disclose cybersecurity risks?
Sign up for free to unlockDoes Medesis Pharma SA offer flexible work?
Sign up for free to unlockDoes Medesis Pharma SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Medesis Pharma SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Medesis Pharma SA conduct supply chain audits?
Sign up for free to unlockDoes Medesis Pharma SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Medesis Pharma SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Medesis Pharma SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Medesis Pharma SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Medesis Pharma SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Medesis Pharma SA disclose water use targets?
Sign up for free to unlockDoes Medesis Pharma SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Medesis Pharma SA have a product recall in the last two years?
Sign up for free to unlockDoes Medesis Pharma SA disclose incidents of discrimination?
Sign up for free to unlockDoes Medesis Pharma SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Medesis Pharma SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Medesis Pharma SA disclose parental leave metrics?
Sign up for free to unlockDoes Medesis Pharma SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Medesis Pharma SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Medesis Pharma SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Medesis Pharma SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Medesis Pharma SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Medesis Pharma SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Medesis Pharma SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Medesis Pharma SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Medesis Pharma SA disclose its waste policy?
Sign up for free to unlockDoes Medesis Pharma SA report according to TCFD requirements?
Sign up for free to unlockDoes Medesis Pharma SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Medesis Pharma SA disclose energy use targets?
Sign up for free to unlockDoes Medesis Pharma SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Medesis Pharma SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Medesis Pharma SA
These potential risks are based on the size, segment and geographies of the company.
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 " NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.